PRS-344/S095012

PD-L1x4-1BB bispecific antibody-anticalin fusion · Servier Bio-Innovation LLC

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for PRS-344/S095012, covering 2025-07-08 to 2026-06-16. Get the full timeline:

Most recent: Clinical Trial Results: A Study of PRS-344/S095012 (PD-L1x4-1BB Bispecific Antibody) in Patients With Solid Tumors [Phase 1, Phase 2]